Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BionetROCO:1784 -0.82%78 FCF Margin % is -2.78% as of Dec. 2025. GuruFocus rates ROCO:1784 with a GF Score™ of 78/100 and a GF Value™ of NT$79.64 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Bionet ranks better than 54.19% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bionet's Free Cash Flow for the
three
months ended in Dec. 2025 was NT$-10 Mil. Bionet's Revenue for the
three
months ended in Dec. 2025 was NT$343 Mil. Therefore, Bionet's FCF Margin % for the quarter that ended in Dec. 2025 was -2.78%.
The historical rank and industry rank for Bionet's FCF Margin % or its related term are showing as below:
ROCO:1784'
s FCF Margin % Range Over the Past 10 Years
Min: -5.17 Med: 0.49 Max: 11.25
Current: 1.28
During the past 13 years, the highest FCF Margin % of Bionet was 11.25%. The lowest was -5.17%. And the median was 0.49%.
ROCO:1784's FCF Margin % is ranked better than 54.19% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.8
vs ROCO:1784: 1.28
Bionet FCF Margin % Related Terms
Bionet FCF Margin % Historical Data
* Premium members only.
The historical data trend for Bionet's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:1784 vs TMO, DHR, IDXX: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Bionet's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionet FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bionet's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Bionet's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionet (ROCO:1784) has a FCF Margin % of -2.78% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bionet and its competitors. According to the industry distribution chart, Bionet ranks #93 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 45.8%.
Is Bionet's FCF Margin % too high?
Bionet's current FCF Margin % is -2.78%. Based on the distribution chart, Bionet ranks #93 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Bionet has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bionet's FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bionet ranks #93 out of 203 companies for FCF Margin %. This puts Bionet in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bionet and its competitors. Bionet's current FCF Margin % is -2.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionet stock overvalued right now?
Based on GuruFocus' analysis, Bionet (ROCO:1784) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$79.64, compared to a current price of NT$60.30 — trading 24.3% below its estimated fair value. The current FCF Margin % is -2.78%. Bionet's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Bionet (ROCO:1784), the current FCF Margin % is -2.78% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionet (ROCO:1784) Overvalued in 2026?
Based on GuruFocus' analysis, Bionet stock appears to be undervalued.
The current stock price of NT$60.30 is trading 24.3% below its estimated GF Value™ of NT$79.64.
GuruFocus considers Bionet to be Modestly Undervalued.
Key valuation signals for ROCO:1784:
FCF Margin %: -2.78%
GF Value™: NT$79.64 vs. price of NT$60.30 (24.3% below fair value)
No single metric tells the full story. See the ROCO:1784 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionet Corp provides blood bank and stem cell services. It is a preservation center for stem cells such as Umbilical Cord Mesenchymal Stem Cells and Dental Pulp Stem Cell Stem.
78GF Score
Get the complete analysis for ROCO:1784
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1784 has been successfully added to your 
